The artus Clostridium difficile QS-RGQ kit from IMDx, Waltham, Mass, has received CE marking for use with QIAsymphony SP/AS and Rotor-Gene Q instruments. IMDx has also submitted a 510(k) premarket notification to the FDA for review. C. difficile is the most common cause of hospital-associated diarrhea and can lead to complications such as pseudomembranous colitis and toxic megacolon when not treated properly. The QS-RGQ kit detects the presence of toxigenic C. difficile in human liquid or soft stool from patients suspected of having C. difficile-associated disease. The test is intended for direct use on patient samples to assist in diagnosis of infection. For more information, visit IMDx.
